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Abstract Previously, we found that calpastatin diminished
transiently prior to myoblast fusion (rat L8 myoblasts), allowing
calpain-induced protein degradation, required for fusion. Here
we show that the transient diminution in calpastatin is due to its
degradation by caspase-1. Inhibition of caspase-1 prevents cal-
pastatin diminution and prevents myoblast fusion. Caspase-1
activity is transiently increased during myoblast di¡erentiation.
Both calpain and caspase appear to be responsible for the fu-
sion-associated membrane protein degradation. Caspase-1 has
been implicated in the activation of proin£ammatory cytokines,
and in cell apoptosis. The involvement of caspase-1 in L8 myo-
blast fusion represents a novel function for this caspase in a non-
apoptotic di¡erentiation process, and points to cross-talk be-
tween the calpain and caspase systems in some di¡erentiation
processes.
) 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Skeletal muscle formation involves myoblast di¡erentiation
and fusion to multinucleated ¢bers [1]. A limited membrane
protein degradation is required, allowing membrane disorga-
nization and creation of fusion-potent domains in fusing cells
[1,2]. Calpain (Ca2þ-dependent intracellular protease) is in-
volved in the fusion-associated protein degradation [3^5].
Most cells, in addition to having one or more of the known
calpain isozymes, contain the speci¢c inhibitor calpastatin,
with ratios of calpain to calpastatin varying among di¡erent
cells [6]. Using red cells as a model system, we showed that the
ratio of calpain to calpastatin determines fusibility [3]. In rat
L8 myoblasts, we found that calpain levels did not change
signi¢cantly during myoblast di¡erentiation, whereas calpa-
statin diminished prior to myoblast fusion and reappeared
after fusion [4]. The transient diminution in calpastatin allows
the Ca2þ-induced calpain activation and protein degradation
in the fusing myoblasts [7].
Calpastatin has a long half-life in dividing cells [8,9]. In
di¡erentiating L8 myoblasts, calpastatin diminution is the re-
sult of inhibition of calpastatin synthesis and decrease in cal-
pastatin stability [9]. The protease responsible for the en-
hanced degradation of calpastatin has not been identi¢ed.
Both calpain and caspase have been shown to degrade calpas-
tatin. Calpain degrades calpastatin in vitro and in some cells
[10,11]. We have found that the calpain inhibitor calpeptin
(which inhibits fusion) does not prevent the diminution in
calpastatin in the inhibited myoblasts [12], indicating that cal-
pastatin degradation in the myoblasts is not due to calpain.
Caspase is known to degrade calpastatin in cell-free extracts
and in several types of cells undergoing apoptosis [13^15].
Caspases have been mainly implicated in apoptosis [16^19],
but may also play roles in processes not involving cell death
[18^22]. Involvement of caspase-3 in skeletal muscle di¡eren-
tiation has recently been described [23]. This newly discovered
activity of caspase-3 provides important evidence for caspase
roles in non-apoptotic events.
Here we show that the transient diminution in calpastatin in
di¡erentiating L8 myoblasts is due to its degradation by cas-
pase, speci¢cally by caspase-1. Caspase-1 has been implicated
primarily in the activation of proin£ammatory cytokines
[16,19,24], and in cell death [25]. The involvement of cas-
pase-1 in myoblast fusion represents a novel function for
this caspase, and points to cross-talk between the calpain
and caspase systems during certain di¡erentiation processes.
2. Materials and methods
2.1. Myoblast cultures, and treatment with caspase and calpain
inhibitors
Rat myoblasts (L8 cell line) were grown in 0.1% gelatin-coated Petri
dishes in Waymouth medium, supplemented with 15% fetal calf se-
rum, and antibiotics (growth medium, GM). Myoblasts were grown in
GM to about 50% con£uency, then induced to di¡erentiate as previ-
ously described [7], by changing the GM medium to Dulbecco’s modi-
¢ed Eagle’s medium, supplemented with 2% horse serum, and four
units of insulin/100 ml (di¡erentiation medium, DM). The time at
which the GM is changed to DM is de¢ned as 0 h. The DM was
replaced every 48 h.
To study e¡ects of caspase inhibition, the following cell permeable
inhibitors were used: the pan-caspase inhibitors benzyloxycarbonyl-
Val-Ala-Asp-£uoromethyl ketone (Z-VAD-FMK) and t-butoxycar-
bonyl-Asp-(OMe)-£uoromethyl ketone (BAF) [26]; the selective cas-
pase-1 inhibitor Boc-Asp(benzyl) chloromethylketone (BACMK) [27];
the selective caspase-3 inhibitor Ac-Asp-Glu-Val-Asp-CMK (Ac-
DEVD-CMK) [28] (Calbiochem, La Jolla, CA, USA). The inhibitors
were dissolved in dimethylsulfoxide (DMSO; 5.0 mM stock solu-
tions); they were added to the DM at 0 h at a ¢nal concentration
of 20 WM Z-VAD-FMK, 5^20 WM BAF, 2.5^5 WM BACMK, and 25
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WM Ac-DEVD-CMK, and replenished every 24 h. The calpain inhib-
itor calpeptin (Calbiochem) was diluted in DM to 25 WM from 25 mM
stock solution in DMSO and added to the myoblasts every 24^48 h,
as described previously [12].
2.2. Measurement of caspase activity in myoblast extracts
Myoblasts, grown in GM (0 h) or cultured in DM for 48^120 h,
were lysed in 10 mM Tris^HCl, pH 7.4, 130 mM NaCl, 10 mM Na-
pyrophosphate, 1% Triton X-100, 10 mM NaH2PO4/Na2HPO4, pH
7.4 (bu¡er A). Lysates were centrifuged and protein concentration in
the supernatants measured (protein assay reagent kit, Pierce Biotech-
nology, Rockford, IL, USA). Supernatants were kept at 320‡C prior
to the estimation of caspase activity. Caspase activity in supernatant
was estimated according to published methods [28] in 20 mM HEPES,
pH 7.4, 2 mM dithiothreitol, 10% glycerol (bu¡er B), using the £uo-
rogenic substrates Ac-YVAD-AMC and Ac-DEVD-AMC (Alexis
Biochemicals, Lausen, Switzerland) for caspase-1 and caspase-3, re-
spectively. Amc release was monitored at 460 nm (excitation at
380 nm), using an FL 600 microplate £uorescence reader (Bio-Tek
Instruments, Winooski, VT, USA).
2.3. Preparation of cell extracts for SDS^PAGE, and immunoblotting
analyses
Myoblast extracts were prepared as previously described [12], using
20 mM Tris^HCl, pH 7.4, 150 mM NaCl, 1% Triton X-100, 2.5 mM
EDTA, 2.5 mM EGTA, and protease inhibitors cocktail set III (Cal-
biochem) (bu¡er C). Aliquots of supernatants were mixed with
Laemmli sample bu¡er for SDS^PAGE.
SDS^PAGE was carried out according to standard procedures, us-
ing 10% or 12% acrylamide. Samples containing 20^40 Wg of myoblast
proteins were electrophoresed, then transferred to nitrocellulose mem-
branes (SchleicherpSchuell). Immunoblotting was carried out as pre-
viously described [12], using as primary antibodies monoclonal anti-W-
calpain antibody, polyclonal anti-m-calpain antibody [12]; polyclonal
anti-calpastatin antibody (R19): Sc-7561 (Santa Cruz Biotechnology,
Santa Cruz, CA, USA) that recognized calpastatin of 110 kDa; poly-
clonal anti-caspase-1 antibody p20 (M-19): Sc-1218 (Santa Cruz);
polyclonal anti-caspase-3 antibody (H-277): Sc-7148 (Santa Cruz);
monoclonal anti-190 kDa talin fragment (antibody speci¢c to cal-
pain-induced talin degradation [29], a gift from Dr. Mitsushi Inomata,
Department of Protein Biochemistry, Tokyo Metropolitan Institute of
Gerontology, Japan); monoclonal anti-L-tubulin antibody (Sigma, St.
Louis, MO, USA); monoclonal anti-K-fodrin antibody (A⁄niti Re-
search Products, Mamhead, UK). The appropriate peroxidase-conju-
gated secondary antibodies were used, and detection of bands was
carried out with ECL (Pierce), as previously described [12]. Mem-
branes were stripped o¡ and reprobed with anti-L-tubulin antibody
for estimation of loading. Bands were quanti¢ed by densitometry.
3. Results
3.1. Myoblast fusion and e¡ects of inhibitors
Myoblasts became con£uent at about 24^48 h after chang-
ing GM to DM. Alignment of myoblasts and start of fusion
was observed at about 72^96 h, followed by fusion to multi-
nucleated myotubes at 120^144 h, as previously described [4].
Previously we found that myoblast fusion was inhibited by the
calpain inhibitors calpeptin and E-64 [12]. In the present
study, to ¢nd out about the e¡ects of caspase inhibition on
myoblast fusion, we used two pan-caspase inhibitors. The
pan-caspase inhibitor Z-VAD-FMK inhibited myoblast fusion
at a concentration of 20 WM. Since Z-VAD-FMK may inhibit
calpain (albeit shown only in vitro) [26], we also used the pan-
caspase inhibitor BAF, which is much more speci¢c as caspase
inhibitor than as calpain inhibitor [26]. BAF inhibited myo-
blast fusion at a concentration of 5 WM. The results indicate
that caspase activity was involved in myoblast fusion. To ¢nd
out which caspase may be responsible for the inhibition, the
selective caspase-1 inhibitor BACMK, and the caspase-3 in-
hibitor Ac-DEVD-CMK were used. BACMK partially inhib-
ited myoblast fusion at a concentration of 2.5 WM (fusion of
about 25% versus 60^80% in the control cultures). Essentially
complete inhibition was achieved at a BACMK concentration
of 5.0 WM (less than 4% fusing cells) (Fig. 1). Ac-DEVD-
CMK did not inhibit myoblast fusion at a concentration of
25 WM (results not shown). Upon removal of BACMK (5
WM), the cells underwent di¡erentiation and fused to myo-
tubes 48^72 h later (Fig. 1), indicating that under the condi-
tions used the inhibitor was not toxic to the cells.
3.2. E¡ects of caspase and calpain inhibitors on myoblast
calpastatin and calpain
The transient diminution in calpastatin that occurred in
control, di¡erentiating myoblasts, was inhibited in BACMK-
treated cells (Fig. 2A). The pan-caspase inhibitors Z-VAD-
FMK and BAF also prevented the diminution in calpastatin
(results not shown). Calpeptin, which inhibited myoblast fu-
sion to the same degree as did the caspase inhibitors, did not
prevent calpastatin diminution, with calpastatin level remain-
Fig. 1. Inhibition of L8 myoblast fusion by the caspase inhibitor BACMK, and reversal of the inhibition. Myoblasts were cultured in DM in
the absence (control) or presence of 5 WM BACMK. 1, Control cells, and 2, BACMK-treated cells cultured in DM for 120 h; 3, BACMK was
removed from treated cultures at 96 h, and cultures continued in DM for an additional 48 h (BACMK removed). M, myotubes. Representative
of three experiments.
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ing low during the culture period (Fig. 2B). No change was
found in W-calpain and m-calpain (as observed by immuno-
blotting), neither during di¡erentiation and fusion in the con-
trol myoblasts, nor in the myoblasts inhibited from fusing by
treatment with BAF or calpeptin (results not shown). Thus,
the results indicate that the transient diminution of calpastatin
in di¡erentiating myoblasts is due to caspase activity, specif-
ically caspase-1.
3.3. Caspase-1 and caspase-3 in di¡erentiating and in inhibited
myoblasts
Activation of caspase-1 and caspase-3 in the myoblasts was
assessed by immunoblotting and by measuring of activity of
cell extracts on caspase substrates. The region of 20^22 kDa
of caspase-1 (mature caspase-1, comprised of multiple species,
and indicative of caspase-1 activation), increased during myo-
blast di¡erentiation, then partially declined; little change was
observed in myoblasts inhibited by BACMK (Fig. 3A). The
activity of caspase-1 in cell extracts increased from very low
level at 0 h to high levels at 72^96 h, then declined; the
Fig. 2. E¡ects of caspase and calpain inhibitors on calpastatin levels
in di¡erentiating myoblasts. Myoblasts were cultured in DM in the
absence or presence of 5 WM BACMK, or 25 WM calpeptin. Myo-
blasts were harvested at various time points, and cell extracts were
analyzed by immunoblotting. Representative of two experiments. A:
E¡ects of BACMK on calpastatin levels in myoblasts cultured in
DM. Calpastatin levels (based on 100% level for 0 h, and using L-
tubulin for normalizing protein loading) were 94% at 48 h, 55% at
96 h and 86% at 120 h in the control myoblasts; in the BACMK-
treated cells, calpastatin levels were 95% at 48 h, 98% at 96 h,
108% at 120 h. B: E¡ects of calpeptin on calpastatin levels in myo-
blasts cultured in DM. Calpastatin levels (based on 100% level for
0 h, and using L-tubulin for normalizing protein loading) were 45%
at 96 h and 82% at 120 h in the control myoblasts; in the calpep-
tin-treated cells, calpastatin levels were 90% at 48 h, 50% at 96 h,
and 63% at 120 h.
Fig. 3. Caspase-1 and caspase-3 in myoblasts during di¡erentiation.
Myoblasts, cultured in DM in the absence or presence of 5 WM
BACMK, were harvested at various time points, and cell extracts
were analyzed. A: Immunoblotting with anti-caspase-1 antibody.
Representative of two experiments. In the control, the ratio of the
mature caspase region to that of the procaspase region (considered
as a ratio of 1.0 at 0 h) increased to 1.8 at 48 h, and 2.14 at 72 h,
then declined to 1.75 at 96 h and 1.48 at 120 h; in the BACMK-
treated cells, the ratio was 1.3^1.1 at 72^120 h. B: Caspase-1 activ-
ity in extracts of myoblasts cultured in DM. Measurements of activ-
ity were carried out by mixing 30 Wl of cell extract in bu¡er A con-
taining 100 Wg of protein with 100 Wl of bu¡er B, containing 40 WM
of the £uorogenic substrate Ac-YVAD-AMC, with and without 40
WM of the inhibitor YVAD-CHO. Amc release (at 460 nm, with ex-
citation at 380 nm) is shown as arbitrary units at the end of 2 h re-
action. Representative of two experiments, each carried out on trip-
licate culture dishes. C: Immunoblotting with anti-caspase-3
antibody. Representative of three experiments.
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addition of the caspase-1 inhibitor Ac-YVAD-CHO resulted
in inhibition of a major part of the activity (Fig. 3B). Caspase-
3 did not change in di¡erentiating myoblasts, as shown by the
same levels of the 32 kDa procaspase present throughout the
culture period and no appearance of lower molecular weight
fractions, which would be indicative of caspase-3 activation
(Fig. 3C). Little activity of caspase-3 was noted in extracts of
dividing myoblasts, without a signi¢cant change in the di¡er-
entiating myoblasts (results not shown). These results indicate
that caspase-1 is activated in the di¡erentiating myoblasts
studied here.
3.4. Protein degradation in di¡erentiating and in
caspase-inhibited myoblasts
The calpain-generated talin 190 kDa fragment [29] was ob-
served in control, fusing myoblasts, with only traces noted in
myoblasts treated with BACMK (Fig. 4A). Fodrin is a known
substrate for both calpain and caspase, with a fodrin fragment
of 150 kDa indicative of caspase and calpain activities, 145
kDa indicative of calpain activity and 120 kDa indicative of
caspase activity [30]. Fodrin fragments of 150/145 kDa and
120 kDa were observed in the di¡erentiating myoblasts, with
little of the 150/145 kDa fractions and no 120 kDa fragment
observed in the BACMK-inhibited myoblasts (Fig. 4B). Lev-
els of myoblast L-tubulin, previously shown not to be a sub-
strate for calpain [7], were the same in di¡erentiating and
inhibited myoblasts; therefore, L-tubulin was used to estimate
loading. The results indicate that calpain-induced degradation
of certain proteins in di¡erentiating, fusing myoblasts can be
inhibited via caspase inhibition.
4. Discussion
The conserved regions in calpastatin are rich in aspartic
acid residues [31] with cleavage motives for caspases [32],
and thus calpastatin is a suitable substrate for caspases. It
has been shown to be a substrate for caspase-1 and caspase-
3, both in vitro and in cells in several cases of apoptosis [13^
15]. Since calpastatin is a substrate for calpain [10,11,30], the
diminution in calpastatin during L8 myoblast di¡erentiation
may have been due to calpain or caspase activity. Calpeptin,
which inhibits calpain, does not prevent calpastatin diminu-
tion in the di¡erentiating myoblasts (for reasons which are not
clear at present, calpeptin also appears to delay or prevent
calpastatin recovery). Thus, calpeptin appears to inhibit fu-
sion by inhibiting calpain activity directly [12]. The results
presented here point to caspase, speci¢cally caspase-1, as the
protease responsible for calpastatin degradation during L8
myoblast di¡erentiation. This conclusion is based on e¡ects
of caspase inhibitors, on immunoblotting analysis and on ac-
tivity estimation in cell extracts. The caspase-1-induced cal-
pastatin degradation would allow calpain activation. In
turn, activated calpain promotes protein degradation, as illus-
trated here by the calpain-induced talin degradation. Fodrin,
which is a substrate for both calpain and caspase, appears to
be degraded in fusing myoblasts by caspase and possibly also
by calpain. Calpastatin subdomains A and C have recently
been shown to be calpain activators [33], and thus some cas-
pase-induced calpastatin fragments may enhance calpain acti-
vation. The presence of such calpastatin fragments may be
responsible for the continuation of calpain-induced protein
degradation at a time when calpastatin has partially recov-
ered.
While this manuscript was being prepared for publication, a
study was published on caspase-3 involvement in mouse skel-
etal muscle di¡erentiation [23]. The caspase-3 substrate mam-
malian sterile twenty-like kinase (MST1) was shown to medi-
ate the caspase-3 e¡ect [23]. Caspase-1 was not evaluated in
that study. The fact that caspase-3 activity is not necessary for
rat L8 myoblast fusion may be due to di¡erences in the levels
and regulation of caspases in di¡erent species and cell types
[13] and/or di¡erences in target substrates (e.g. MST1 [23]). It
is also possible that the rat L8 myoblasts studied here are
beyond the stage of myoblast di¡erentiation at which cas-
pase-3 is involved. The triggers for caspase activation in the
myoblasts are not known. It is of interest to note that the
anti-apoptotic protein bcl-2 is expressed in the early stages
of myogenesis in proliferating myoblasts but not in di¡eren-
tiating myoblasts [18,34]. It is also of interest to note that the
transcription factor FKHR, that usually induces cell cycle
arrest and apoptosis, is required for mouse myoblast fusion
[35]. The relation of FKHR activity to the loss of bcl-2 and to
caspase activation in di¡erentiating myoblasts remains to be
studied.
Overall, the published results [23] and those presented here
indicate that one or more of the caspases are involved in
myoblast di¡erentiation and fusion. The participation of cas-
pases in non-apoptotic processes may be ascribed to partial
activation of caspase cascades, so that some initial steps oc-
cur, but the reactions do not proceed to apoptosis [18^23]. In
Fig. 4. Protein degradation in myoblasts. Myoblasts were cultured
in DM, in the absence and presence of 5 WM BACMK. Cells were
harvested at various time points and analyses by immunoblotting.
A: Immunoblotting with antibody to calpain-generated talin frag-
ment. Representative of two experiments. B: Immunoblotting with
anti-K-fodrin antibody. Representative of two experiments.
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the case of myoblast di¡erentiation, such partial caspase-
mediated events might play a role in the membrane and cy-
toskeleton disorganization required for myoblast fusion to
viable myotubes. Most studies have concentrated on cas-
pase-3 as the downstream e¡ector caspase in non-apoptotic
events [19^23]. Information is lacking on caspase-1 in such
processes, including di¡erentiation processes, and it would
be of interest to carry out such studies on other myoblasts
and other cell types. We have recently found that neuronal
cell di¡erentiation is inhibited by caspase-1 inhibitor (S. Bar-
noy, T. Vaisid, and N.S. Kosower, unpublished results). Thus,
caspase-1 involvement in cell di¡erentiation may not be
unique to L8 myoblasts. The involvement of caspase-1 in L8
myoblast fusion represents a novel function for this caspase
and points to cross-talk between the calpain and caspase sys-
tems in some cases of non-apoptotic, di¡erentiation processes.
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